covid
Buscar en
Revista Colombiana de Cardiología
Toda la web
Inicio Revista Colombiana de Cardiología Derrame pericárdico con inminente taponamiento cardiaco secundario a inhibidor ...
Journal Information
Vol. 18. Issue 2.
Pages 119-123 (March - April 2011)
Share
Share
Download PDF
More article options
Vol. 18. Issue 2.
Pages 119-123 (March - April 2011)
Open Access
Derrame pericárdico con inminente taponamiento cardiaco secundario a inhibidor de la tirosina quinasa. Reporte de un caso
Pericardial effusion secondary to tyrosine kinase inhibitor with imminence of cardiac tamponade: case report
Visits
3392
Andrés F. Buitrago1,4,
Corresponding author
abuitrag@uniandes.edu.co

Correspondencia: Dr. Andrés Felipe Buitrago Sandoval, Hospital Universitario Fundación Santa Fe, Calle 119 No. 7-75. Bogotá, Colombia. Tel (57-1) 6 03 03 03. Ext.: 5492.
, Luis E. Silva1,2,4, Leidy P. Prada1,4, Libardo Lobato1,3,4
1 Hospital Universitario Fundación Santa Fe de Bogotá. Bogotá, Colombia
2 Universidad de Los Andes. Bogotá, Colombia
3 Universidad El Bosque. Bogotá, Colombia
4 Trabajo realizado en el Hospital Universitario Fundación Santa Fe de Bogotá, Departamento de Medicina Interna. Bogotá, Colombia
This item has received

Under a Creative Commons license
Article information

La leucemia es una enfermedad maligna que se caracteriza por una proliferación no controlada de una clona iniciada en una etapa precoz de la diferenciación linfoide. Es importante determinar si hay una alteración genética conocida como cromosoma Filadelfia, para pronóstico y tratamiento. El imatinib, un inhibidor de la tirosina kinasa, tiene buena respuesta terapéutica y pocos efectos adversos. Uno de frecuente aparición es la serositis manifestada como derrame pleural, aunque es de menor incidencia asociada con derrame pericárdico. El tratamiento se debe individualizar, pero en caso de inminente taponamiento cardiaco se realiza pericardiocentesis.

Palabras clave:
imatinib
inhibidores de la tirosina quinasa
derrame pericárdico

Leukemia is a malignant disease characterized by uncontrolled proliferation of a clone initiated at an early stage of lymphoid differentiation. It is important to determine if there is a genetic disorder known as the Philadelphia chromosome, for both prognosis and treatment. Imatinib, a tyrosine kinase inhibitor has good therapeutic response and few adverse effects. An adverse event is the frequent occurrence of serositis manifested as pleural effusion, but its association with pericardial effusion has a lower incidence. Treatment should be individualized, but in case of imminent cardiac tamponade pericardiocentesis is performed.

Keywords:
imatinib
tyrosine kinase inhibitors
pericardial effusion
Full text is only aviable in PDF
Bibliografía
[1.]
F. Cuéllar.
Leucemias agudas del niño y del adulto.
Fundamentos de Medicina Interna. Hematología, 6ª, Corporación para Investigaciones Biológicas, (2004), pp. 123-126
[2.]
M. Rodríguez, A.F. Cardona, L. Enciso, et al.
Leucemia mieloide crónica en crisis blástica: bases moleculares y diagnóstico (parte I).
Rev Colom Carcerol, 10 (2006), pp. 257-266
[3.]
A. Arora, M. Eric.
Scholar. Role of tyrosine kinase inhibitors in cancer therapy.
J Pharmacol Exper Therap, 315 (2005), pp. 971-979
[4.]
F. Ravandi, P. Kebriaei.
Philadelphia -positive acute lymphoblastic leukemia.
Hematol Oncol Clin North Am, 23 (2009), pp. 1043-1063
[5.]
M.A. Gómez, I.A. Morel, L.D. Ramírez, D.S. Gómez.
Efectos adversos del mesilato de imatinib en el tratamiento de la leucemia mieloide crónica.
Rev Pos Cátedra Med, 174 (2007), pp. 16-19
[6.]
K.T. Carpiuc, J.M. Stephens, M.F. Botteman, W. Feng, J.W. Hay.
A review of the clinical and economic outcomes of imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia.
Expert Opin Pharmacother, 8 (2007), pp. 2775-2787
[7.]
H. Joensuu, J.C. Trent, P. Reichardt.
Practical management of tyrosine kinase inhibitorassociated side effects in GIST.
Cancer Treat Rev, 37 (2011), pp. 75-88
[8.]
C.D. Blanke, C. Rankin, G.D. Demetri, et al.
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.
J Clin Oncol, 26 (2008), pp. 626-632
[9.]
G.S. Orphanos, G.N. Ioannidis, A.G. Ardavanis.
Cardiotoxicity induced by tyrosine kinase inhibitors.
Acta Oncol, 48 (2009), pp. 964-970
[10.]
R. Kerkela, L. Grazette, R. Yacobi, C. Iliescu, R. Patten, C. Beahm, et al.
Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.
Nat Med, 12 (2006), pp. 908-916
[11.]
K. Kelly, R. Swords, D. Mahalingam, S. Padmanabhan, F.J. Giles.
Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors.
Target Oncol, 4 (2009), pp. 99-105
[12.]
R.J. Motzer, T.E. Hutson, P. Tomczak, M.D. Michaelson, R.M. Bukowski, O. Rixe, et al.
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.
N Engl J Med, 356 (2007), pp. 115-124
[13.]
P. van der Geer, T. Hunter, R.A. Lindberg.
Receptor proteintyrosine kinases and their signal transduction pathways.
Annu Rev Cell Biol, 10 (1994), pp. 251
[14.]
M. Talpaz, N. Shah, H. Kantarjian, N. Donato, J. Nicoll, R. Paquette, et al.
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias.
N Engl J Med, 354 (2006), pp. 2531-2541
[15.]
A. Quintas-Cardama, et al.
Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure.
J Clin Oncol, 25 (2007), pp. 3908-3914
[16.]
R. Pieters, W.L. Carroll.
Biology and treatment of acute lymphoblastic leukemia.
Hematol Oncol Clin North Am, 24 (2010), pp. 1-18
[17.]
M.S. Ribeiro Marcolino, H.N.S. Bittencourt, M.M. Barbosa, M.C.P. Nunes, V.F. Xavier, N.C.D. Clementino.
An evaluation of the cardiotoxicity of imatinib mesylate.
Leukemia Research, 32 (2008), pp. 1809-1814
[18.]
E. Atallah, J.B. Durand, H. Kantarijan, J. Cortes.
Congestive heart failure is a rare event in patient receiving imatinib therapy.
Blood, 110 (2007),
Copyright © 2011. Sociedad Colombiana de Cardiología y Cirugía Cardiovascular
Download PDF
Article options